Bonviva 3 mg solution for injection

Bonviva belongs to a group of medicines called bisphosphonates. It contains ibandronic acid. It does not contain hormones.

Bonviva may reverse bone loss by stopping more loss of bone and increasing bone mass in most women who take it, even though they won?t be able to see or feel a difference. Bonviva may help lower the chances of breaking bones (fractures). This reduction in fractures was shown for the spine but not for the hip.

Bonviva 3 mg solution for injection in pre-filled syringes is a solution for intravenous injection by a health care professional. Do not inject Bonviva yourself.

Bonviva is prescribed to you to treat postmenopausal osteoporosis because you have an increased risk of fractures. Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause. At the menopause, a woman?s ovaries stop producing the female hormone, oestrogen, which helps to keep her skeleton healthy.

The earlier a woman reaches the menopause, the greater her risk of fractures in osteoporosis. Other things that can increase the risk of fractures include:

• not enough calcium and vitamin D in the diet
• smoking cigarettes, or drinking too much alcohol
• not enough walking or other weight-bearing exercise
• a family history of osteoporosis

Many people with osteoporosis have no symptoms. If you have no symptoms you may not know if you have the condition. However, osteoporosis makes you more likely to break bones if you fall or hurt yourself. A broken bone after the age of 50 may be a sign of osteoporosis. Osteoporosis can also cause back pain, height loss and a curved back.

Bonviva prevents loss of bone from osteoporosis, thus helping to rebuild lost bone. Therefore, Bonviva makes bones less likely to break.

A healthy lifestyle will also help you to get the most benefit from your treatment. This includes eating

a balanced diet rich in calcium and vitamin D, walking or other weight-bearing exercise, not smoking and not drinking too much alcohol.

Do not receive Bonviva

• if you have, or had in the past , low blood calcium. Please consult your doctor
• if you are allergic (hypersensitive) to ibandronic acid or any of the other ingredients in Bonviva injection

Take special care with Bonviva

Some patients need to be especially careful when using Bonviva. Tell your doctor:

• if you have or have ever had kidney problems, kidney failure or have needed dialysis, or if you have any other disease that may affect your kidneys
• if you have any disturbance of mineral metabolism (such as vitamin D deficiency)
• You should take calcium and vitamin-D supplements while receiving Bonviva. If you are unable to do so, you should inform your doctor.
• If you are under dental treatment or will undergo dental surgery, tell your dentist that you are being treated with Bonviva.

Taking other medicines
Tell your doctor, nurse or pharmacist if you are taking, or have recently taken, any other medicines. Mention to your doctor, nurse or pharmacist anything you are taking which you bought over the counter, without a prescription.

Pregnancy and breast-feeding

You should not be given Bonviva if you are pregnant, or if there is a possibility you may become pregnant. If you are breast-feeding, you will need to stop breast-feeding in order to receive Bonviva. Ask your doctor or pharmacist for advice before taking any medicines.

Driving and using machines
You can drive and use machines as it?s very unlikely that Bonviva will affect your ability to drive and use machines.

Important information about some of the ingredients of Bonviva

This medicinal product contains less than 1 mmol sodium (23 mg) per dose (3 ml), i.e. essentially ?sodium-free?.

The recommended dose of Bonviva for the intravenous injection is 3 mg (1 pre-filled syringe) once every 3 months.

The injection should be given into the vein by a physician or qualified/trained health care worker. Do not administer the injection to yourself.

The solution for injection must be administered into a vein only, and not anywhere else in the body.

Continuing to receive Bonviva

To get the most benefit from the treatment it is important to continue receiving the injections every 3 months for as long as your doctor prescribes it for you. Bonviva can treat osteoporosis only for as long as you keep receiving the treatment, even though you will not be able to see or feel a difference.

You should also take calcium and vitamin-D supplements, as recommended by your doctor.

If too much Bonviva is given

You may develop low levels of calcium, phosphorus or magnesium in the blood. Your doctor may take steps to correct such changes and may give you an injection containing these minerals.

If a dose of Bonviva is missed

You should arrange an appointment to get the next injection as soon as possible. After that, go back to getting the injections every 3 months from the date of the most recent injection.

Like all medicines, Bonviva can cause side effects, although not everybody gets them.

Talk to a nurse or a doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:

• rash, itching, swelling of your face, lips, tongue and throat, with difficulty breathing. You may be having an allergic reaction to the medicine.
• severe pain in the chest, severe pain after swallowing food or drink, severe nausea, or vomiting.
• flu-like symptoms (if any effects become troublesome or last more than a couple of days).
• pain or sore in your mouth or jaw
• eye pain and inflammation (if prolonged)

Other possible side effects

Common (affects less than 1 in 10 people)

• headache
• heartburn, stomach pain (such as ?gastroenteritis? or ?gastritis?), indigestion, nausea, having diarrhoea or constipation
• rash
• pain or stiffness in your muscles, joints, or back
• flu-like symptoms (including fever, shaking and shivering, feeling of discomfort, fatigue, bone pain and aching muscles and joints)
• fatigue

Uncommon (affects less than 1 in 100 people)

• bone pain
• feeling weak
• dizziness
• flatulence
• inflammation of a vein and pain or injury at the injection site

Rare (affects less than 1 in 1000 people):

• hypersensitivity reaction; swelling of the face, lips and mouth (see allergy)
• itching
• eye pain or inflammation

Very rare (affects less than 1 in 10000 people)

• a condition involving exposed bone in the mouth called ?osteonecrosis of the jaw?.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Keep out of the reach and sight of children.

This medicinal product does not require any special storage conditions.

Do not use Bonviva 3 mg solution for injection in pre-filled syringes after the expiry date which is stated on the carton and on the syringe after ?EXP?. The expiry date refers to the last day of that month.

The person giving the injection should throw away any unused solution and put the used syringe and injection needle into an appropriate disposal container.

What Bonviva 3 mg solution for injection in pre-filled syringes contains

• The active substance is ibandronic acid. One pre-filled syringe contains 3 mg of ibandronic acid in 3 ml of solution (as 3.375 mg of ibandronic acid, monosodium salt, monohydrate).
• The other ingredients are sodium chloride, acetic acid, sodium acetate trihydrate and water for injections

What Bonviva 3 mg solution for injection in pre-filled syringes looks like and contents of the pack

Bonviva 3 mg solution for injection in pre-filled syringes is a clear colourless solution. Each pre-filled syringe contains 3 ml of solution. Bonviva is available in packs of 1 pre-filled syringe and 1 injection needle or 4 pre-filled syringes and 4 injection needles.
Not all pack sizes may be marketed.

Marketing Authorisation Holder

Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom

Manufacturer

Roche Pharma AGEmil-Barell-Strasse 1D-79639 Grenzach-Wyhlen Germany

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

LuxembourgLuxemburg Voirsiehe BelgiqueBelgien BelgiëBelgiqueBelgien N.V. Roche S.A. TélTel 32 0 2 525 82 11

359 2 818 44 44 Magyarország Roche Magyarország Kft. Tel 36 - 23 446 800

eská republika Roche s. r. o. Tel 420 - 2 20382111 Malta GlaxoSmithKline Malta Tel 356 21 238131

Danmark Roche as Tlf 45 - 36 39 99 99 Nederland Roche Nederland B.V. Tel 31 0 348 438050

Deutschland Roche Pharma AG Tel 49 0 7624 140 Norge Roche Norge AS Tlf 47 - 22 78 90 00

Österreich Roche Austria GmbH Tel 43 0 1 27739 Eesti GlaxoSmithKline Eesti OÜ Tel 372 - 6 676 900 estoniagsk.com

Roche Hellas A.E. 30 210 61 66 100 Polska Roche Polska Sp.z o.o. Tel 48 - 22 345 18 88

España Roche Farma S.A. Tel 34 - 91 324 81 00 Portugal Roche Farmacêutica Química, Lda Tel 351 - 21 425 70 00

France Roche Tél 33 0 1 46 40 50 00 România Roche România S.R.L. Tel 40 21 206 47 01

Ireland Roche Products Ireland Ltd. Tel 353 0 1 469 0700 Slovenija Roche farmacevtska druba d.o.o. Tel 386 - 1 360 26 00

Slovenská republika Roche Slovensko, s.r.o. Tel 421 - 2 52638201 Ísland Roche as co Icepharma hf Tel 354 540 8000

Italia Roche S.p.A. Tel 39 - 039 2471 SuomiFinland Roche Oy PuhTel 358 0 10 554 500

K GlaxoSmithKline Cyprus Ltd 357 - 22 39 70 00 Sverige Roche AB Tel 46 0 8 726 1200

Latvija GlaxoSmithKline Latvia SIA Tel 371 -6 7312687 United Kingdom Roche Products Ltd. Tel 44 0 1707 366000

Lietuva

UAB ?GlaxoSmithKline Lietuva?
Tel: +370 5 2 649000
info.lt@gsk.com

This leaflet was last approved in {date}

----------------------------------------------------------------------------------------------------------------------------- This information is intended for medical or healthcare professionals only.

INFORMATION FOR THE HEALTHCARE PROFESSIONALS

Please see the Summary of Product Characteristics for more information.

Administration of Bonviva 3 mg solution for injection in pre-filled syringe:

Bonviva 3 mg solution for injection in pre-filled syringe should be injected intravenously over a period of 15 - 30 seconds.

The solution is irritant, therefore strict adherence to the intravenous route of administration is important. If you inadvertently inject into the tissues around the vein, patients may experience local irritation, pain and inflammation at the injection site.

Bonviva 3 mg solution for injection in pre-filled syringe must not be mixed with calcium-containing solutions (such as Ringer-Lactate solution, calcium heparin) or other intravenously administered medicinal products. Where Bonviva is administered via an existing intravenous infusion line, the intravenous infusate should be restricted to either isotonic saline or 50 mg/ml (5 %) glucose solution.

Missed dose:

If a dose is missed, the injection should be administered as soon as convenient. Thereafter, injections should be scheduled every 3 months from the date of the last injection.

Overdose:

No specific information is available on the treatment of overdosage with Bonviva.

Based on knowledge of this class of compounds, intravenous overdosage may result in hypocalcaemia, hypophosphataemia, and hypomagnesaemia, which can cause paraesthesia. In severe cases intravenous infusion of appropriate doses of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, may be needed.

General advice:

Bonviva 3 mg solution for injection in pre-filled syringe like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values.

Hypocalcaemia and other disturbances of bone and mineral metabolism should be assessed and effectively treated before starting Bonviva injection therapy. Adequate intake of calcium and vitamin D is important in all patients. All patients must receive supplemental calcium and vitamin D.

Patients with concomitant diseases, or who use medicinal products which have a potential for undesirable effects on the kidney, should be reviewed regularly in line with good medical practice during treatment.

Any unused solution for injection, syringe and injection needle should be disposed of in accordance with local requirements.